Danaher(NYSE) DHR

Danaher NYSE:DHR makes tools for scientists and doctors to study diseases. These products help labs run tests and develop new medicines. The company helps health experts find ways to treat patients.

Tools for Science and Health

• Biotechnology: Equipment, consumables, and software used to develop biological medicines; generated $1,807 million of total sales in the third quarter of 2026.
• Life Sciences: Instruments and services for studying DNA, RNA, and proteins; accounted for $1,865 million of total sales in the third quarter of 2026.
• Diagnostics: Clinical instruments and software used by hospitals to diagnose disease; generated $2,882 million of total sales in the third quarter of 2026.

Growth Through Strategic Acquisitions

• Acquired Masimo for approximately $9.8 billion on June 10, 2026, to expand patient monitoring technology offerings.
• Added a business to the Life Sciences segment in 2026 for $37 million in upfront cash.
• Invested $86 million in non-marketable equity securities during the nine-month period ended Sept. 25, 2026.

Speed and Precision in the Lab

The company uses the Danaher Business System to improve productivity and cost-efficiencies across its global operations. These internal processes help the company manage a strong presence in high-growth regions, which represented 31% of total sales in the third quarter of 2026. This focus on operational efficiency supports the integration of new businesses into its three core segments.

Important Financial Figures

• Total sales reached $6.6 billion in the third quarter of 2026, up 8.5% year over year.
• Net earnings from continuing operations were $1.2 billion in the three-month period ended Sept. 25, 2026.
• Operating cash flows reached $4.7 billion during the nine-month period ended Sept. 25, 2026, up 10% year over year.
• Cash and cash equivalents totaled $5.7 billion as of Sept. 25, 2026.

The Company Evolution

Danaher has transitioned from a diversified industrial company into a global science and technology specialist. Its focus on the Danaher Business System and targeted acquisitions supports its growth in the healthcare and life sciences markets.